Page 8 - Ut Southwestern Gene Therapy Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Taysha Gene Therapies Expands Leadership Team with the Appointment of Chief Development Officer

Published: May 13, 2021 Mary Newman, former SVP of Regulatory Affairs at Astellas Gene Therapies, joins Taysha with over 30 years of experience in regulatory affairs and research and development in the biotech industry Extensive experience deeply rooted in gene therapy at Astellas Gene Therapies, Audentes Therapeutics and BioMarin DALLAS (BUSINESS WIRE) Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced the most recent addition to its leadership team with the appointment of industry veteran Mary Newman as Chief Development Officer. Ms. Newman will oversee program and portfolio management, as well as translational sciences, and will report to Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM, Taysha’s Chief Medical Officer

Suyash prasadDevelopment officerBayer healthcare pharmaceuticals incHead of researchShire ltdRegulatory affairsBerlex incRegulatory affairs at biomarin pharmaceutical incTaysha gene therapies incRegulatory affairs at astellas gene therapiesSarcode bioscience incSequus pharmaceuticals incOregon state universityUt southwestern gene therapy programGene therapiesOmary newman

Taysha Gene Therapies Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Progra

Taysha Gene Therapies Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Progra
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

United statesKimberly leeSuyash prasadSteven grayHead of researchCompany contactDevelopment of tayshaNational institutes of healthDrug administrationExchange commissionTaysha gene therapies incCorporate communicationsEuropean medicines agencyDevices agencyNational institute of neurological disordersUt southwestern gene therapy program

Taysha Gene Therapies Reports Full-Year 2020 Financial Results and Provides a Corporate Update

Taysha Gene Therapies Reports Full-Year 2020 Financial Results and Provides a Corporate Update
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

United statesNorth carolinaLaura sepp lorenzinoKathy reapeExchange commissionDevelopment rd expensesTaysha gene therapies incQueen universityHealth canadaUt southwestern gene therapy programGene therapiesScientific advisory boardCleveland clinicGood manufacturing practicesChief medical officerSpark therapeutics

Taysha Gene Therapies Continues to Add Significant Gene Therapy Expertise to Leadership Team with the Appointment of Chief Legal Officer and Chief People Officer

Taysha Gene Therapies Continues to Add Significant Gene Therapy Expertise to Leadership Team with the Appointment of Chief Legal Officer and Chief People Officer
manchestertimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from manchestertimes.com Daily Mail and Mail on Sunday newspapers.

United statesKimberly leeTimothyj dourosTracym porterCarolyn hawleyCompany contactDartmouth collegeCanale communicationsCounsel at bluebird bio incCubist pharmaceuticals incInternational counselUniversity of north carolina at greensboroTaysha gene therapies incBoston college law schoolHuman developmentBayer healthcare

Taysha Gene Therapies Receives Rare Pediatric Disease and Orphan Drug Designations for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5 Deficiency

Published: Jan 19, 2021 DALLAS (BUSINESS WIRE) Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced that it has received both rare pediatric disease and orphan drug designations from the U.S. Food and Drug Administration (FDA) for TSHA-105, an AAV9-based gene therapy in development for SLC13A5-related epilepsy. “There are no approved therapies for epilepsy caused by SLC13A5 that address the underlying cause of this disease,” said RA Session II, President, Founder and CEO of Taysha. “We are encouraged by the early evidence of TSHA-105’s disease-modifying approach and believe these designations will help us potentially accelerate the development of this exciting program. We look forward to working with the FDA to make TSHA-105 available to patient

United statesKim nyeRachel baileyRare pediatric disease priority review voucher programExchange commissionOffice of orphan products developmentResearch foundationUt southwestern gene therapy programAssistant professorPediatric neurologyOrphan products developmentGene therapiesGene therapy programPrivate securities litigation reform actQuarterly reportTaysha gene therapies receives rare pediatric disease and orphan drug designations for tsha 105 the treatment of epilepsy caused by slc13a5 deficiency